Tandem Diabetes Care Files 2025 Proxy Statement
Ticker: TNDM · Form: DEF 14A · Filed: 2025-04-08T00:00:00.000Z
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: TNDM
TL;DR
Tandem Diabetes Care (TNDM) proxy filing out. Details exec pay & board for FY24.
AI Summary
Tandem Diabetes Care Inc. filed its DEF 14A proxy statement on April 8, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, board of directors, and other corporate governance matters. Key financial data for the years 2020 through 2024 is included, providing a historical overview of the company's performance.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions on important company matters.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal changes in executive compensation or governance that may impact investor confidence and stock performance.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the proxy statement.)
- 20250408 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- TANDEM DIABETES CARE INC (company) — Filer
- San Diego (location) — Business Address City
- DE (location) — State of Incorporation
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual or special meeting of shareholders. It provides detailed information about matters to be voted on, such as the election of directors, executive compensation, and other corporate actions.
When is the fiscal year end for Tandem Diabetes Care Inc. as reported in this filing?
The fiscal year end for Tandem Diabetes Care Inc. is December 31, as indicated by the 'CONFORMED PERIOD OF REPORT: 20241231'.
What is the filing date of this DEF 14A statement?
This DEF 14A statement was filed on April 8, 2025, as indicated by 'FILED AS OF DATE: 20250408'.
Where is Tandem Diabetes Care Inc. headquartered?
Tandem Diabetes Care Inc. is headquartered in San Diego, California, with its business and mail address listed as 12400 High Bluff Drive, San Diego, CA 92130.
What is the SIC code for Tandem Diabetes Care Inc.?
The Standard Industrial Classification (SIC) code for Tandem Diabetes Care Inc. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
From the Filing
0001438133-25-000058.txt : 20250408 0001438133-25-000058.hdr.sgml : 20250408 20250408171034 ACCESSION NUMBER: 0001438133-25-000058 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250408 DATE AS OF CHANGE: 20250408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 25822807 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 DEF 14A 1 tndm-20250408.htm DEF 14A 2025 PROXY STATEMENT tndm-20250408 0001438133 DEF 14A FALSE iso4217:USD 0001438133 2024-01-01 2024-12-31 0001438133 2023-01-01 2023-12-31 0001438133 2022-01-01 2022-12-31 0001438133 2021-01-01 2021-12-31 0001438133 2020-01-01 2020-12-31 0001438133 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001438133 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001438133 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001438133 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001438133 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001438133 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001438133 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001438133 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001438133 1 2024-01-01 2024-12-31 0001438133 2 2024-01-01 2024-12-31 0001438133 3 2024-01-01 2024-12-31 0001438133 4 2024-01-01 2024-12-31 0001438133 5 2024-01-01 2024-12-31   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934   Filed by the Registrant x Filed by a Party other than the Registrant ☐  Check the appropriate box:   ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐  Definitive Additional Materials ☐  Soliciting Material under 240.14a-12 Tandem Diabetes Care, Inc .   (Name of Registrant as Specified In Its Charter)   (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed in table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11.     Notice of Annual Meeting of Stockholders DATE May 21, 2025 TIME 3:00 p.m. Pacific Time MEETING WEB ADDRESS www.virtualshareholdermeeting.com/TNDM2025 Dear Stockholders: You are cordially invited to attend the 2025 Annual Meeting of Stockholders of Tandem Diabetes Care, Inc., or the Annual Meeting, which will be held on Wednesday, May 21, 2025 at 3:00 p.m., Pacific Time. The Annual Meeting will be held virtually by live internet webcast at www.virtualshareholdermeeting.com/TNDM2025. We are holding the Annual Meeting for the following purposes, as more fully described in the accompanying Proxy Statement: 1. To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders. 2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers as discl